DAVION HEALTHCARE PLC

F-1/A amended

25,000,000 shares

DAVION HEALTHCARE PLC filed an F-1/A amendment to its registration statement for a direct listing of 25,000,000 ordinary shares on Nasdaq, emphasizing no underwriter involvement and secondary shareholder sales. The amendment addresses SEC comments with enhanced disclosures on the opening auction process, financial advisor roles, resale mechanics, and appointment of two additional directors. The filing highlights risks associated with the direct listing structure and market volatility.

8-A12B effective

DAVION HEALTHCARE PLC filed an 8-A12B to register ordinary shares for trading on Nasdaq, following the effectiveness of its F-1 registration statement. The filing confirms the direct listing of 25 million shares, with no underwriters involved. The company emphasizes that shares will be traded directly by registered shareholders, subject to Rule 415 resale provisions.

F-1/A amended

25,000,000 shares

DAVION HEALTHCARE PLC filed an F-1/A registration statement for a direct listing of 25,000,000 ordinary shares on Nasdaq. The filing emphasizes that the offering is a secondary offering by registered shareholders, with no shares being sold by the issuer. The company highlights its focus on medical devices and diagnostics, with an expected opening price of $12 per share. The registration is not a time-bound offering and remains effective until withdrawal or modification.

F-1/A amended

Price $10.00 · 25,000,000 shares

DAVION HEALTHCARE PLC's F-1/A filing details a direct listing of 25,000,000 ordinary shares by registered shareholders, not an IPO. The filing clarifies that no shares are offered by the issuer, with shares registered for secondary trading on Nasdaq. Revere Securities LLC serves as corporate advisor and lead market maker, with no underwriter involved. The opening price will be determined by Nasdaq's auction process. The filing emphasizes compliance with SEC rules for foreign private issuers and includes forward-looking statements disclaimer.

F-1 filed

DAVION HEALTHCARE PLC is registering 25,000,000 Ordinary Shares for a direct listing on NASDAQ under the ticker 'DAVI', with no new securities being offered. The company develops non-invasive home diagnostic tests for early health anomaly detection, including cancers, and is structured as a foreign private issuer and emerging growth company under U.S. regulations. The filing emphasizes compliance with NASDAQ listing requirements and highlights its focus on Class I medical devices with global regulatory approvals.